LU80880A1 - Derives d'alkylenediamines - Google Patents
Derives d'alkylenediamines Download PDFInfo
- Publication number
- LU80880A1 LU80880A1 LU80880A LU80880A LU80880A1 LU 80880 A1 LU80880 A1 LU 80880A1 LU 80880 A LU80880 A LU 80880A LU 80880 A LU80880 A LU 80880A LU 80880 A1 LU80880 A1 LU 80880A1
- Authority
- LU
- Luxembourg
- Prior art keywords
- radical
- amino
- methyl
- compounds
- compounds according
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 15
- 150000003254 radicals Chemical class 0.000 claims description 9
- -1 Alkylenediamine amides Chemical class 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- XPXMKIXDFWLRAA-UHFFFAOYSA-N hydrazinide Chemical compound [NH-]N XPXMKIXDFWLRAA-UHFFFAOYSA-N 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- HWIIAAVGRHKSOJ-UHFFFAOYSA-N 2-chloro-6,7-dimethoxyquinazolin-4-amine Chemical compound ClC1=NC(N)=C2C=C(OC)C(OC)=CC2=N1 HWIIAAVGRHKSOJ-UHFFFAOYSA-N 0.000 description 1
- UNIJBMUBHBAUET-UHFFFAOYSA-N 3-(methylamino)propanenitrile Chemical compound CNCCC#N UNIJBMUBHBAUET-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 201000004239 Secondary hypertension Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- YWGHUJQYGPDNKT-UHFFFAOYSA-N hexanoyl chloride Chemical compound CCCCCC(Cl)=O YWGHUJQYGPDNKT-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000004675 pentylcarbonyl group Chemical group C(CCCC)C(=O)* 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- ZRHANBBTXQZFSP-UHFFFAOYSA-M potassium;4-amino-3,5,6-trichloropyridine-2-carboxylate Chemical compound [K+].NC1=C(Cl)C(Cl)=NC(C([O-])=O)=C1Cl ZRHANBBTXQZFSP-UHFFFAOYSA-M 0.000 description 1
- NDCKJWQCEZPQOJ-UHFFFAOYSA-N propane-1,2-diamine;hydrochloride Chemical compound Cl.CC(N)CN NDCKJWQCEZPQOJ-UHFFFAOYSA-N 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7803175A FR2421888A1 (fr) | 1978-02-06 | 1978-02-06 | Amides d'alkylene-diamines et leur application en therapeutique |
| FR7803175 | 1978-02-06 | ||
| FR7836819 | 1978-12-29 | ||
| FR7836819A FR2445323A2 (fr) | 1978-02-06 | 1978-12-29 | Amides d'alkylenediamines et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU80880A1 true LU80880A1 (fr) | 1980-09-24 |
Family
ID=26220430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU80880A LU80880A1 (fr) | 1978-02-06 | 1979-02-05 | Derives d'alkylenediamines |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US4315007A (de) |
| JP (1) | JPS6023114B2 (de) |
| AT (1) | AT365176B (de) |
| AU (1) | AU521524B2 (de) |
| BE (1) | BE873909A (de) |
| CA (1) | CA1102330A (de) |
| CH (1) | CH637122A5 (de) |
| DE (1) | DE2904445C2 (de) |
| DK (1) | DK159316C (de) |
| ES (1) | ES477457A1 (de) |
| FI (1) | FI66861C (de) |
| FR (2) | FR2421888A1 (de) |
| GB (1) | GB2013679B (de) |
| GR (1) | GR66846B (de) |
| IE (1) | IE47812B1 (de) |
| IL (1) | IL56578A (de) |
| IT (1) | IT1192347B (de) |
| LU (1) | LU80880A1 (de) |
| NL (2) | NL181482C (de) |
| NO (1) | NO151463C (de) |
| NZ (1) | NZ189553A (de) |
| PT (1) | PT69178A (de) |
| SE (1) | SE449360B (de) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2466462A2 (fr) * | 1978-02-06 | 1981-04-10 | Synthelabo | Derives d'alkylenediamines, leur preparation et leur application en therapeutique |
| DE3380093D1 (en) * | 1982-09-30 | 1989-07-27 | William John Louis | 3-aminopropoxyphenyl derivatives, their preparation and pharmaceutical compositions containing them |
| FR2577804B1 (fr) * | 1985-02-26 | 1987-03-27 | Synthelabo | Compositions pharmaceutiques a base de verapamil et d'alfuzosine |
| FR2570275B1 (fr) * | 1984-09-14 | 1986-11-21 | Synthelabo | Compositions pharmaceutiques a base de diltiazem et d'alfusozine |
| FR2577803B1 (fr) * | 1985-02-26 | 1987-04-03 | Synthelabo | Compositions pharmaceutiques a base de nifedipine et d'alfuzosine |
| EP0189336A1 (de) * | 1985-01-18 | 1986-07-30 | Synthelabo | Pharmazeutische Zusammensetzungen mit Gehalt an einem alpha-Blocker und an einem Calcium-Antagonisten |
| FR2582513B1 (fr) * | 1985-05-28 | 1988-08-05 | Synthelabo | Compositions pharmaceutiques contenant de l'alfuzosine |
| LU86672A1 (fr) * | 1986-11-19 | 1988-06-13 | Oreal | Composition pour induire et stimuler la croissance des cheveux et diminuer la chute a base de derives d'alkylene diamino quinazoline |
| YU70890A (en) * | 1989-04-21 | 1992-05-28 | Egyt Gyogyszervegyeszeti Gyar | Process for obtaining quinazoline derivatives |
| IL101243A (en) * | 1991-03-20 | 1999-12-22 | Merck & Co Inc | Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history |
| FR2694495B1 (fr) * | 1992-08-05 | 1994-09-23 | Synthelabo | Préparation pharmaceutique transdermique contenant de l'alfuzosine. |
| JPH07206857A (ja) * | 1993-12-28 | 1995-08-08 | Synthelabo Sa | アルフゾシン塩酸塩の二水和物 |
| FR2717388B1 (fr) * | 1994-03-21 | 1996-11-22 | Synthelabo | Formes galéniques à libération prolongée du chlorhydrate d'alfuzosine. |
| US6313294B1 (en) | 1998-02-04 | 2001-11-06 | Development Center For Biotechnology | Process for preparing amides |
| CN1768745A (zh) | 1998-09-30 | 2006-05-10 | 武田药品工业株式会社 | 改善膀胱排泄能力的药物 |
| AU2001240150A1 (en) * | 2000-03-13 | 2001-09-24 | Chemrx Advanced Technologies, Inc. | Quinazoline synthesis |
| US20020065286A1 (en) * | 2000-08-21 | 2002-05-30 | Davies Michael John | Treatment of wounds |
| US20020091129A1 (en) * | 2000-11-20 | 2002-07-11 | Mitradev Boolell | Treatment of premature ejaculation |
| GB0130219D0 (en) * | 2001-12-18 | 2002-02-06 | Pfizer Ltd | Compounds for the treatment of sexual dysfunction |
| US20030229001A1 (en) * | 2002-01-31 | 2003-12-11 | Pfizer Inc. | Treatment of male sexual dysfunction |
| GB0219961D0 (en) | 2002-08-28 | 2002-10-02 | Pfizer Ltd | Oxytocin inhibitors |
| US7323462B2 (en) * | 2002-12-10 | 2008-01-29 | Pfizer Inc. | Morpholine dopamine agonists |
| KR20050085563A (ko) | 2002-12-13 | 2005-08-29 | 워너-램버트 캄파니 엘엘씨 | 하부요로증상을 치료하기 위한 알파-2-델타 리간드 |
| CA2451267A1 (en) * | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| PA8597401A1 (es) * | 2003-03-14 | 2005-05-24 | Pfizer | Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep |
| US20040220186A1 (en) * | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| US20050065158A1 (en) * | 2003-07-16 | 2005-03-24 | Pfizer Inc. | Treatment of sexual dysfunction |
| US7291640B2 (en) * | 2003-09-22 | 2007-11-06 | Pfizer Inc. | Substituted triazole derivatives as oxytocin antagonists |
| US20050267096A1 (en) * | 2004-05-26 | 2005-12-01 | Pfizer Inc | New indazole and indolone derivatives and their use pharmaceuticals |
| US20050288270A1 (en) * | 2004-05-27 | 2005-12-29 | Pfizer Inc | New aminopyridine derivatives and their use as pharmaceuticals |
| ATE394395T1 (de) * | 2004-09-16 | 2008-05-15 | Hetero Drugs Ltd | Kristalline alfuzosinbase |
| WO2006100588A1 (en) * | 2005-03-21 | 2006-09-28 | Pfizer Limited | Substituted triazole derivatives as oxytocin antagonists |
| US7618972B2 (en) * | 2005-03-21 | 2009-11-17 | Pfizer Inc | Substituted triazole derivatives as oxytocin antagonists |
| CA2618103A1 (en) * | 2005-08-10 | 2007-02-15 | Pfizer Limited | Substituted triazole derivatives as oxytocin antagonists |
| US20070066824A1 (en) * | 2005-09-22 | 2007-03-22 | Anumula Raghupathi R | Preparation of alfuzosin |
| US20070105880A1 (en) * | 2005-11-08 | 2007-05-10 | Torrent Pharmaceuticals Limited | Process for the preparation of alfuzosin |
| US20090069562A1 (en) * | 2005-12-26 | 2009-03-12 | Joseph Prabahar Koilpillai | Process for the preparation of alfuzosin |
| CN100564376C (zh) * | 2006-09-19 | 2009-12-02 | 浙江华纳药业有限公司 | 阿夫唑嗪的制备方法 |
| CN101190890B (zh) * | 2006-11-30 | 2011-04-27 | 江苏豪森药业股份有限公司 | 5-[(2r)-[2-[2-[2-(2,2,2-三氟乙氧基)苯氧基]乙基]氨基]丙基]-2-甲氧基苯磺酰胺 |
| US20080160081A1 (en) * | 2006-12-11 | 2008-07-03 | Mutual Pharmaceutical Company, Inc. | Alfuzosin formulations, methods of making, and methods of use |
| US20100092556A1 (en) * | 2006-12-11 | 2010-04-15 | Kristin Arnold | Alfuzosin formulations, methods of making, and methods of use |
| WO2008152514A2 (en) | 2007-05-04 | 2008-12-18 | Actavis Group Ptc Ehf | Process for the preparation of alfuzosin and salts thereof |
| WO2009001369A1 (en) * | 2007-06-22 | 2008-12-31 | Alembic Limited | An improved process for the preparation of alfuzosin hydrochloride |
| WO2009007987A1 (en) * | 2007-07-11 | 2009-01-15 | Alembic Limited | An improved process for the preparation of alfuzosin and its novel polymorph |
| CA2695076A1 (en) * | 2007-08-02 | 2009-02-05 | Rajendra Narayanrao Kankan | Process for the preparation of alfuzosin hydrochloride |
| US20090076043A1 (en) * | 2007-09-19 | 2009-03-19 | Protia, Llc | Deuterium-enriched alfuzosin |
| US20100183717A1 (en) * | 2009-01-16 | 2010-07-22 | Kristin Arnold | Controlled-release formulations |
| CN107998090A (zh) * | 2017-12-30 | 2018-05-08 | 威海贯标信息科技有限公司 | 一种阿夫唑嗪片组合物 |
| CN113801069B (zh) * | 2020-06-15 | 2024-03-15 | 鲁南制药集团股份有限公司 | 一种盐酸阿夫唑嗪中间体化合物 |
| CN114573569B (zh) * | 2022-03-30 | 2023-07-04 | 邦恩泰(山东)生物医药科技集团股份有限公司 | 一种异喹啉类化合物的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3663706A (en) * | 1969-09-29 | 1972-05-16 | Pfizer | Use of 2,4-diaminoquinazolines as hypotensive agents |
| US4026894A (en) * | 1975-10-14 | 1977-05-31 | Abbott Laboratories | Antihypertensive agents |
| US4060615A (en) * | 1976-02-18 | 1977-11-29 | Mead Johnson & Company | 2-Piperazinyl-6,7-dimethoxyquinazolines |
| FR2362630A1 (fr) * | 1976-08-24 | 1978-03-24 | Synthelabo | Derives d'alkylenediamines |
| DK140695C (da) * | 1976-05-07 | 1980-05-12 | Synthelabo | Analogifremgangsmaade til fremstilling af 2,4-diamino-6,7-dimethoxyquinazolinderivater eller syreadditionssalte heraf |
| FR2350101A1 (fr) * | 1976-05-07 | 1977-12-02 | Synthelabo | Nouvelles guanidines cyclisees |
| FR2389613A2 (en) * | 1977-05-05 | 1978-12-01 | Synthelabo | Antihypertensive 4-amino-6,7-di:methoxy-quinazolyl alkylene di:amine - prepd. from a 2-halo-quinazoline and an alkylene di:amine |
-
1978
- 1978-02-06 FR FR7803175A patent/FR2421888A1/fr active Granted
- 1978-12-29 FR FR7836819A patent/FR2445323A2/fr active Granted
-
1979
- 1979-02-02 BE BE0/193248A patent/BE873909A/xx not_active IP Right Cessation
- 1979-02-02 AU AU43895/79A patent/AU521524B2/en not_active Expired
- 1979-02-02 NZ NZ189553A patent/NZ189553A/xx unknown
- 1979-02-02 DK DK046079A patent/DK159316C/da not_active IP Right Cessation
- 1979-02-02 IL IL56578A patent/IL56578A/xx unknown
- 1979-02-02 GR GR50581A patent/GR66846B/el unknown
- 1979-02-05 ES ES477457A patent/ES477457A1/es not_active Expired
- 1979-02-05 LU LU80880A patent/LU80880A1/fr unknown
- 1979-02-05 CH CH112079A patent/CH637122A5/fr not_active IP Right Cessation
- 1979-02-05 JP JP54012737A patent/JPS6023114B2/ja not_active Expired
- 1979-02-05 SE SE7900987A patent/SE449360B/sv not_active IP Right Cessation
- 1979-02-05 FI FI790369A patent/FI66861C/fi not_active IP Right Cessation
- 1979-02-05 PT PT7969178A patent/PT69178A/pt active IP Right Revival
- 1979-02-05 NO NO790358A patent/NO151463C/no unknown
- 1979-02-05 IT IT19908/79A patent/IT1192347B/it active Protection Beyond IP Right Term
- 1979-02-05 CA CA320,864A patent/CA1102330A/en not_active Expired
- 1979-02-05 IE IE210/79A patent/IE47812B1/en not_active IP Right Cessation
- 1979-02-05 AT AT0084279A patent/AT365176B/de not_active IP Right Cessation
- 1979-02-06 GB GB79403279A patent/GB2013679B/en not_active Expired
- 1979-02-06 DE DE2904445A patent/DE2904445C2/de not_active Expired
- 1979-02-06 NL NLAANVRAGE7900917,A patent/NL181482C/xx not_active IP Right Cessation
- 1979-12-10 US US06/099,622 patent/US4315007A/en not_active Expired - Lifetime
-
1993
- 1993-05-28 NL NL930043C patent/NL930043I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU80880A1 (fr) | Derives d'alkylenediamines | |
| FR2500450A1 (fr) | Nouveaux derives aminomethyl-5 oxazolidiniques, leur procede de preparation et leur application en therapeutique | |
| CH653021A5 (fr) | Derives piperidino, piperazino et homopiperazino, n-substitues par un groupe heterocyclique aromatique, leur procede de preparation et composition therapeutique les contenant. | |
| FR2641278A1 (fr) | Piperidines, procedes de preparation et medicaments les contenant | |
| EP0021940B1 (de) | Aminoderivate von Benzothiazol, Verfahren zu ihrer Herstellung und ihre Anwendung in der Heilkunde | |
| LU82236A1 (fr) | 9-aminoalkylfluorenes, leur preparation et leur utilisation therapeutique | |
| EP0360685A1 (de) | 1-[(Diarylmethoxy)alkyl]-pyrrolidine und -piperidine, Verfahren zu ihrer Herstellung und Arzneimittel, die sie enthalten | |
| FR2483929A1 (fr) | Nouvelles adenosines n6-substituees utiles comme medicaments antihypertenseurs, compositions therapeutiques et formes pharmaceutiques les contenant, et leur procede de preparation | |
| EP0000452B1 (de) | 1,2,4-Oxadiazolderivate, ihre Herstellung und Verwendung als Arzneimittel | |
| US4145422A (en) | Aminomethylene oxindoles | |
| CA1338637C (fr) | Derives de la dihydro-1,4 pyridine, leurs procedes de preparation et les compositions pharmaceutiques les renfermant | |
| EP0605667A1 (de) | Sigma rezeptor selektive diamin-derivate | |
| FR2547822A1 (fr) | Acylpiperazinoquinazolines substituees utiles comme medicaments et procede pour leur preparation | |
| FR2466462A2 (fr) | Derives d'alkylenediamines, leur preparation et leur application en therapeutique | |
| CH655721A5 (fr) | Derives du furanne et sels d'addition de ces derives leurs procedes de preparation et composition pharmaceutique les contenant. | |
| EP0055145B1 (de) | 4-(Aminomethyl)cyclohexan-1-carbonsäure-derivate | |
| EP0275762B1 (de) | Indol-Carboxamid-Derivate und ihre Salze, Verfahren und Zwischenprodukte zur Herstellung, Anwendung als Heilmittel und Zusammenstellungen, die sie enthalten | |
| EP0275221B1 (de) | N-(1H-indol-4-yl)-Benzamidderivate, ihre Salze und deren Anwendung als Heilmittel und Zusammenstellungen, die sie enthalten | |
| EP0347305B1 (de) | [(Aryl-4-piperazinyl-1)-2-ethoxy]-3p-cymole, die ortho-, meta-, para-monosubstituierten oder disubstituierten Derivate, das Verfahren zu deren Herstellung und die als aktives Prinzip diese Verbindungen enthaltenden Arzneimittel | |
| FR2584070A1 (fr) | Nouveaux derives de l'hydroxy alkoxy 4-phenyl propyl indole, leurs sels, procede et intermediaires de preparation, application a titre de medicaments et compositions les renfermant. | |
| US4176191A (en) | Aminomethylene oxindoles | |
| EP0157762B1 (de) | Substituierte, piperidinoguanidine, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen | |
| FR2468595A2 (fr) | Amides d'alkylene diamines, leur preparation et leur application en therapeutique | |
| EP0103500A2 (de) | Phenethyl-1-alpha-phenyl-piperidin-3-propannitril-Derivate, ihre Herstellung und therapeutische Verwendung | |
| EP0003456A1 (de) | 3-Amino-cardenolidderivate, Verfahren zu ihrer Herstellung und Arzneimittel, die diese enthalten |